Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05171049 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
A Phase 3 study, sponsored by Anthos Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,150
- Enrollment target
NCT05171049: Clinical Trial Phase 3 study, sponsored by Anthos Therapeutics.
NCT05171049 is a Phase 3 study that was terminated before completion, run by Anthos Therapeutics. The registered enrollment target is 1,150 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (49% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05171049, a Phase 3 study, was terminated before completion, sponsored by Anthos Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,150 participants
- Enrollment target
Study Summary
This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)
Primary Outcome
Time to first event of centrally adjudicated venous thromboembolism (VTE) recurrence
Interventions
- DRUG Apixaban
- BIOLOGICAL Abelacimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,150 participants |
| Start Date | 2022-05-05 |
| Est. Completion | 2026-02-04 |
| Phase | Phase 3 |
Why NCT05171049 stopped before completion
NCT05171049 is an interventional study that assigns participants to a tested intervention. Its 1,150 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (49% higher).
The record links to 0 conditions, and to 2 interventions - of which Apixaban is the first listed.
NCT05171049 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05171049 about?
NCT05171049 is a clinical study titled "A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE". This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)
What is the current status of trial NCT05171049?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,150 participants. The study started on 2022-05-05. Estimated completion is 2026-02-04.
What interventions are being tested in trial NCT05171049?
The interventions under investigation include: Apixaban (DRUG), Abelacimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05171049?
This trial is sponsored by Anthos Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05171049's enrollment target sits among peer trials
1,150 238th of 2000 higher than 1,759 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06408181 · 1,150 participants · Phase 3
APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia
- NCT06528314 · 1,150 participants · Phase 3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- NCT07293559 · 1,150 participants
Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States
- NCT07339423 · 1,150 participants · Phase 3
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI